Randomized trials comparing Telmisartan vs. Valsartan and Losartan 24-hour ambulatory blood pressure control, GLP-1 heart failure outcomes, UKPDS 34 cardiovascular mortality reductions, and statin + ezetimibe ApoB targets. Explore 714 indexed studies and multi-trial syntheses with verified PubMed PMIDs, participant sample sizes (N), and Absolute vs. Relative Risk numbers.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
Combined use of statins, amlodipine, and renin-angiotensin-aldosterone system inhibitors improves the blood-pressure-lowering response and endothelial function in patients with high blood pressure and diabetes.
Although losartan-based therapy reduced ventricular mass more, greater heart rate reduction with atenolol resulted in larger reduction of the triple product.
The adipocytokine levels obtained with barnidipine+losartan were significantly better than those obtained with telmisartan+hydrochlorothiazide (P<0.05 for all parameters).
Compared with standard statin single-drug treatment, the combination of statin plus ezetimibe showed greater coronary plaque regression, which might be attributed to cholesterol absorption inhibition-induced aggressive lipid...
This study provides insight into physicians' perspectives on clinical management of high cholesterol and highlights a gap in knowledge translation from guidelines to clinical practice.
L50/H12.5/A5 was well tolerated.
Contrary to our original hypothesis, the ML phase was not associated with sympathoexcitation or exaggerated heart and blood vessel reactivity in sleep-deprived premenopausal women.
Amlodipine was effective in reducing the absolute values of systolic and diastolic BP during resistance exercise and in preventing the progressive increase in diastolic BP that occurs over sets of low-intensity exercise.
Combination therapy with an ARB plus a CCB may be preferable to that with an ARB plus diuretics for decreasing BP variability.
PS added to LLT can further improve lipid profile, without additional effects on intestinal sterol absorption or synthesis.
Mean changes in diastolic and systolic BP were sustained for 44 weeks.
LPO levels were reduced in both statin arms after 16 weeks of treatment (p < 0.05 versus baseline), without changes in the placebo group.
Based on an informal comparison with atorvastatin, this represents a three-fold greater potency.
It is concluded that atorvastatin is more potent than ezetimibe in improving the serum lipid profile, reducing oxidative stress, suppressing inflammation and preserving endothelial function, while ezetimibe may be advantageous...
The present systematic review and meta-analysis does not support a causal role between TS and adverse CV events.
Our data show, first, that azelnidipine, compared with amlodipine, exerted a favorable effect on sympathetic nerve activity, without affecting baroreflex sensitivity, in hypertensive patients.
No correlations between these markers and LDL-cholesterol or CRP were observed.
Four years of early MHT did not affect progression of atherosclerosis despite improving some markers of CVD risk.
BMI status does not modify the effects of blood-pressure-lowering medications on BP control or heart and blood vessel disease outcomes.
Incident AF is substantially less common among black than nonblack hypertensive patients.
Patients with OSA appear to have increased high cholesterol (high total cholesterol, LDL, TG, and low HDL).
Amlodipine reduced the risk of total heart and blood vessel events as well as all-cause mortality compared with non-CCB-based regimens, indicating its benefit for high-risk cardiac patients.
At 52 weeks, evolocumab added to diet alone, to low-dose atorvastatin, or to high-dose atorvastatin with or without ezetimibe significantly reduced LDL cholesterol levels in patients with a range of heart and blood vessel risks.
With the precautions stipulated by the protocol of the ONTARGET trial, hypokalemia and hyperkalemia were infrequent events.
Titers of LDL(-) were not modified by the treatments.
In selected patients with a history of statin-related myalgia whose symptoms are difficult to evaluate, n-of-1 trials may be a useful method for determining statin tolerability.
Limitations include a small sample size, limited power to detect CPC changes and lack of normal controls for comparison.
The BP lowering effect with amlodipine/losartan and amlodipine/valsartan was comparable.
Short-term add-on therapy with losartan reduced B-type natriuretic peptide levels in patients hospitalized for decompensated severe heart failure and low cardiac output with inotrope dependence.
Telmisartan resulted in significantly greater reduction in arterial stiffness index (ASI) in left and right lower limb arterial bed (39.9 ± 11.7 vs.
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
